Trials / Completed
CompletedNCT02007278
Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride
Glycemic Excursions in Type 2 Diabetic Patients Treated With Vildagliptin and Metformin (GalvusMet) Versus Glimepiride and Metformin
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to compare the effect of a fixed dose combination of vildagliptin plus metformin versus combination therapy of glimepiride plus metformin in glycemic variability in patients with type 2 diabetes who have not achieved adequate control of their disease prior to treatment with metformin monotherapy in optimal doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vildagliptin and metformin (combination) | vildagliptin and metformin combination therapy as 50mg/850mg bid or 50mg/1000mg bid |
| DRUG | glimepiride | |
| DRUG | Metformin |
Timeline
- Start date
- 2014-01-03
- Primary completion
- 2016-02-22
- Completion
- 2016-02-22
- First posted
- 2013-12-10
- Last updated
- 2017-07-11
- Results posted
- 2017-07-11
Locations
8 sites across 1 country: Colombia
Source: ClinicalTrials.gov record NCT02007278. Inclusion in this directory is not an endorsement.